VentriPoint Appoints Mary-Pierre Waiss Vice President of Clinical Development



    SEATTLE, July 1 /CNW/ -- VentriPoint Diagnostics (TSX: VPT) today
announced that it has appointed Mary-Pierre Waiss vice president of clinical
development.
    Waiss brings 25 years of experience in the field of cardiac imaging to
VentriPoint.  She is currently a research scientist in the Cardiovascular
Research Lab at the University of Washington.  In this capacity, she collects
and analyzes data, as well as evaluates and develops protocols related to the
anatomy, function and volume calculations of the right ventricle.
    "Mary-Pierre's experience in cardiac imaging will be beneficial as we
continue the development of the VentriPoint Diagnostic System," said Joseph
Ashley, president and CEO of VentriPoint Diagnostics.  "We especially look
forward to her contributions in the collection and analysis of data as we
finalize our first databases in anticipation of commercial sales in early
2009."
    Waiss has held positions at Children's Hospital of Boston, Seattle
Children's Hospital & Regional Medical Center and Group Health Cooperative.
    Waiss received her bachelor's degree in Diagnostic Ultrasound from
Seattle University and is registered by the ARDMS with specialty in adult and
pediatric echocardiography.  She is a member of the American Society of
Echocardiography, the American Heart Association and the Western Washington
Society of Echo.
    
    About VentriPoint Diagnostics
    
    VentriPoint creates diagnostic tools to monitor patients with heart
disease -- the number one cause of death in developed countries.  By using
images produced from existing medical imaging systems, the VentriPoint
Diagnostic System generates critical heart measurements in a rapid and
inexpensive manner not currently available.  This breakthrough diagnostic tool
is based upon technology received by VentriPoint through its technology
license with the University of Washington.  The VentriPoint Diagnostic System,
together with its associated online service, is being developed for a variety
of heart related disease states, including congenital heart disease.

    For further information, please contact:

    
                    Edward Garth, Chief Financial Officer
                         VentriPoint Diagnostics Ltd.
                     Telephone:  (206) 283-0221, ext. 402
                          Facsimile:  (206) 283-2309
    
    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.

    
    Media Contacts:
    VentriPoint Media Contacts:
    Russo Partners LLC
    Ian Stone
    (619) 814-3510
    ian.stone@russopartnersllc.com
    




For further information:

For further information: Edward Garth, Chief Financial Officer of 
VentriPoint Diagnostics Ltd., +1-206-283-0221, ext. 402, Facsimile, 
+1-206-283-2309; or Media, Ian Stone of Russo Partners LLC for VentriPoint 
Diagnostics Ltd., +1-619-814-3510, ian.stone@russopartnersllc.com

Organization Profile

VENTRIPOINT DIAGNOSTICS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890